# Nefecon and Ambrisentan in IgA Nephropathy

Study · id `cardio:ct-nct07030894` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07030894](<https://clinicaltrials.gov/study/NCT07030894>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07030894

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 129 participants.

## Technical summary

Registry record NCT07030894. Allocation not applicable; no masking; primary purpose treatment. Start 2025-09-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 129 participants (planned count; ClinicalTrials.gov record NCT07030894, source copy `cardio:ctgov-nct07030894-2025-09-15`, retrieved 2026-10-26)
- Started: 2025-09-01 (actual) (ClinicalTrials.gov record NCT07030894, source copy `cardio:ctgov-nct07030894-2025-09-15`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT07030894, source copy `cardio:ctgov-nct07030894-2025-09-15`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT07030894, source copy `cardio:ctgov-nct07030894-2025-09-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07030894, source copy `cardio:ctgov-nct07030894-2025-09-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07030894-2025-09-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Nefecon and Ambrisentan in IgA Nephropathy
- Acronym: BAIN
- Condition: IgA Nephropathy
- Condition: Chronic Kidney Disease
- Condition: Proteinuria
- Intervention (Drug): "Nefecon®","Ambrisentan"
- Lead sponsor: The First Hospital of Jilin University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: The First Hospital of Jilin University (`cardio:org-the-first-hospital-of-jilin-university`)

## Provenance

Content hash: 1342a128c12f851f10d43223ea4aa3018dce35a6b22ab8bc2826c177d8d01916
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
